CARLSBAD - Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that EOS Catalyst will be introduced at the 2023 NASS Annual Meeting.

EOS Catalyst builds on the already unprecedented functionality of the EOS imaging platform with automated alignment and surgical planning capabilities.

'EOS is foundational to ATEC's mission to revolutionize spine surgery,' said Pat Miles, Chairman and Chief Executive Officer. 'Catalyst will be the first reflection of our influence on EOS' technological prowess, accelerating the informatics sophistication of the platform with capabilities that will objectively improve the predictability and reproducibility of spine care, from straightforward surgery to complex deformity, including adolescent idiopathic scoliosis treatment. We're excited to fully release Catalyst in 2024 and champion a step forward for spine - no other platform will be able to replicate EOS' influence on patient care.'

Dr. Vedat Deviren, MD, Spine Surgeon and Professor of Orthopaedic Surgery at the UCSF Medical Center, added, 'EOS imaging is a requirement for successful outcomes in both long and short-segment spine surgery, which is why I have relied on its high-quality images and alignment information in my surgical planning process for three years. I can't wait to incorporate the groundbreaking workflow efficiencies and clinical predictability that EOS Catalyst will make possible. I will be able to enter surgery with an informed template and customized rods, then intra-operatively reconcile to plan. Ultimately, the data collection that is underway will found our industry's first predictive care capabilities. The end-to-end solutions offered by EOS Catalyst will become the standard of care.'

About EOS Catalyst

EOS Catalyst integrates information and data collection throughout the surgical experience through a cloud-based platform. The initial Catalyst release will include the following: Automatic, quantified alignment assessment. AI-driven alignment information with level-labeling and color-coded patient benchmarking to normative values will be available minutes after an EOS exam.

3D-surgical planning. 3D-modelling of the patient's spine and alignment will more easily designate patients for surgery.

Patient-specific pre-bent rods. Seamless ordering, approval and delivery of pre-bent rods for short and long construct surgery will improve intra-operative sagittal correction.

Intra-operative reconciliation. Full-spine intra-operative measurements of key coronal and sagittal parameters throughout surgery will inform objective comparisons to the pre-operative plan and enable exportation for post-operative analysis.

The Company expects the Catalyst platform, which is currently under limited evaluation, to be released in mid-2024.

About ATEC

ATEC, through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company dedicated to revolutionizing the approach to spine surgery through clinical distinction. ATEC's Organic Innovation Machine is focused on developing new approaches that integrate seamlessly with the Company's expanding AlphaInformatiX Platform to better inform surgery and more safely and reproducibly achieve the goals of spine surgery. ATEC's vision is to be the Standard Bearer in Spine.

Forward Looking Statements

This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described therein. Forward-looking statements include references to the Company's expectations with respect to future revenue and growth and planned commercial launches, introductions, integration, regulatory submissions or clearances. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: failure to achieve acceptance of the Company's products by the surgeon community and the uncertainty of success in developing new products or products currently in the pipeline. The words 'believe,' 'will,' 'should,' 'expect,' 'intend,' 'estimate,' 'look forward' and 'anticipate,' and variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

Contact:

Tina Jacobsen

Tel: (760) 494-6790

Email: investorrelations@atecspine.com

(C) 2023 Electronic News Publishing, source ENP Newswire